Cover Image
市場調查報告書

全身性紅斑性狼瘡 (SLE) :主要國家的市場預測 (2016∼2026年)

Epiomic Epidemiology Series: Systemic Lupus Erythematosus Forecast in 8 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 353262
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
全身性紅斑性狼瘡 (SLE) :主要國家的市場預測 (2016∼2026年) Epiomic Epidemiology Series: Systemic Lupus Erythematosus Forecast in 8 Major Markets 2016-2026
出版日期: 2016年02月01日 內容資訊: 英文 48 Pages
簡介

全身性紅斑性狼瘡 (SLE) ,特徵是對核及細胞質抗原的自我抗體反應的自體免疫疾病。SLE是徵兆與症狀廣泛的全身性疾病,是症狀反復復發與緩解的慢性疾病。SLE影響皮膚、關節、腎臟、腦、身體的血液細胞及其他的器官的功能及外表。

本報告提供全球主要9個國家 (美國、法國、德國、義大利、西班牙、英國、巴西以及日本) 的全身性紅斑性狼瘡 (SLE) 的發病情形相關分析,疾病概要和目前的患病人數,性別、各年代 (5歲間隔) 的詳細情況,各地區、各民族趨勢,風險要素,疾病診斷預後,主要的症狀和併發症,未來趨勢預測 (今後10年份) 的資訊彙整,為您概述為以下內容。

圖表

簡介

病因

危險因素和預防

疾病診斷

變異:各地區/民族

疾病預後和臨床過程

疾病相關的主要併發症/特徵

患者數的定量化的方法

全身性紅斑性狼瘡 (SLE) 的最大患病人數

SLE患者的特徵

  • SLE的發病類型
  • 神經精神病的徵兆
  • SLE的補體價值
  • SLE的抗體
  • SLE相關的關節痛
  • 心肺有關
  • 血液疾病
  • 皮膚病變

狼瘡性腎炎的特徵

簡稱

相關出版

患者為基礎的線上資料庫

患者為基礎的產品

價格的線上資料、平台

參考文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: SLES0010216

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Systemic Lupus Erythematosus in 8 Major Markets

Systemic Lupus Erythematosus (SLE) is an autoimmune disease, characterised by an autoantibody response to nuclear and cytoplasmic antigens. It is a systemic disease, with a large spectrum of signs and symptoms. It is a chronic condition that follows a relapsing and remitting course of its associated manifestations. It can affect the functions and appearance of skin, joints, kidneys, brain, the body's blood cells and other organs.

This report provides the current prevalent population for SLE across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of SLE have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for SLE include:

  • Osteoporosis
  • Infections
  • Skin lesions & conditions
  • Arthritis
  • Anaemia
  • Raynaud's phenomenon
  • Serositis
  • Lupus Nephritis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global SLE's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of SLE and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on SLE's prevalent population.
  • Identify sub-populations within SLE which require treatment.
  • Gain an understanding of the specific markets that have the largest number of SLE patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/ Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Systematic Lupus Erythematosus
  • Features of SLE Patients
    • SLE Onset Type
    • Neuropsychiatric Manifestations
    • Complement Levels in SLE
    • Anti-bodies in SLE
    • Associated Joint Pain of SLE
    • Cardio-Pulmonary Involvement
    • Haematological Disorders
    • Cutaneous Involvements
  • Features of Lupus Nephritis Patients
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables & Figures

  • ACR Classification Criteria for SLE
  • WHO morphologic classification of lupus nephritis
  • Prevalence of SLE, total (000s)
  • Prevalence of SLE, males (000s)
  • Prevalence of SLE, females (000s)
  • Onset type of SLE in patients, total (000s)
  • Neuropsychiatric manifestations in SLE patients, total (000s)
  • Level of cognitive dysfunction in SLE patients, total (000s)
  • Prevalence of hypocomplementemia in SLE patients, total (000s)
  • SLE patients with low levels of complement, total (000s)
  • SLE patients with anti-nuclear antibodies, total (000s)
  • SLE patients with anti-DNA antibodies, total (000s)
  • SLE patients with anti-Ro (SSA) antibodies, total (000s)
  • SLE patients with anti-La (SSB) antibodies, total (000s)
  • Prevalence of SLE patients with arthritis, total (000s)
  • Prevalence of SLE patients with Jaccoud's arthritis, total (000s)
  • Prevalence of SLE patients with osteonecrosis, total (000s)
  • Carotid plaque burden in SLE patients, total (000s)
  • Prevalence of serositis, total (000s)
  • Serositis associated conditions in SLE patients, total (000s)
  • Prevalence of haematological disorders, total (000s)
  • Types of haematological disorders in SLE patients, total (000s)
  • Prevalence of cutaneous involvement in SLE patients, total (000s)
  • Prevalence of specific dermatological conditions, total (000s)
  • Prevalence of lupus nephritis, total (000s)
  • Prevalence of renal replacement in lupus nephritis patients, total (000s)
  • Severity of lupus nephritis by WHO class, total (000s)
  • Abbreviations and Acronyms used in the Report
  • USA Prevalence of SLE by 5-yr age cohort, males (000s)
  • USA Prevalence of SLE by 5-yr age cohort, females (000s)
  • France Prevalence of SLE by 5-yr age cohort, males (000s)
  • France Prevalence of SLE by 5-yr age cohort, females (000s)
  • Germany Prevalence of SLE by 5-yr age cohort, males (000s)
  • Germany Prevalence of SLE by 5-yr age cohort, females (000s)
  • Italy Prevalence of SLE by 5-yr age cohort, males (000s)
  • Italy Prevalence of SLE by 5-yr age cohort, females (000s)
  • Spain Prevalence of SLE by 5-yr age cohort, males (000s)
  • Spain Prevalence of SLE by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of SLE by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of SLE by 5-yr age cohort, females (000s)
  • Brazil Prevalence of SLE by 5-yr age cohort, males (000s)
  • Brazil Prevalence of SLE by 5-yr age cohort, females (000s)
  • Japan Prevalence of SLE by 5-yr age cohort, males (000s)
  • Japan Prevalence of SLE by 5-yr age cohort, females (000s)
Back to Top